Study to Evaluate the Safety and Pharmacokinetics of ALMB-0166 in Patients With Acute Spinal Cord Injury
About this trial
This trial is enrolling individuals with acute (less than 72 hours), incomplete cervical and thoracic spinal cord injuries to test the safety, tolerability and overall activity in the body (pharmacokinetics) of an experimental drug (ALMB-0166). The drug is believed to reduce local inflammation and scar formation, thus improving nerve growth and recovery. If included, participants will either receive a single dose of: 1) the active drug; or 2) a placebo (inactive) drug. Outcomes will be followed for up to 2 months.
Included participants
What’s involved
Type
Details
Participants will either receive a single dose of 1) the active drug or 2) the placebo within 72 hours after injury.
Potential benefits
Main benefits
General health
Additional benefits
Good to know: Potential benefits are defined as outcomes that are being measured during and/or after the trial.
Wings for Life supports SCITrialsFinder
Wings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.
Learn more- Trial recruitment status
- Unknown
- Trial start date
- 15 Apr 2022
- Organisation
- AlaMab Therapeutics (Shanghai) Inc.
- Trial recruitment status
- Unknown
- Trial start date
- 15 Apr 2022
- Organisation
- AlaMab Therapeutics (Shanghai) Inc.
About this trial
Included participants
What’s involved
Potential benefits
Wings for Life supports SCITrialsFinder
Wings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.
Learn more